Yee, Douglas http://orcid.org/0000-0002-3387-4009
Isaacs, Claudine http://orcid.org/0000-0002-9646-1260
Wolf, Denise M.
Yau, Christina
Haluska, Paul
Giridhar, Karthik V. http://orcid.org/0000-0003-4640-9197
Forero-Torres, Andres
Jo Chien, A.
Wallace, Anne M.
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Albain, Kathy S.
Ellis, Erin D.
Beckwith, Heather
Haley, Barbara B.
Elias, Anthony D.
Boughey, Judy C.
Kemmer, Kathleen
Yung, Rachel L.
Pohlmann, Paula R. http://orcid.org/0000-0001-7914-5162
Tripathy, Debu http://orcid.org/0000-0002-5711-2404
Clark, Amy S. http://orcid.org/0000-0002-3685-6535
Han, Hyo S.
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Khan, Qamar J. http://orcid.org/0000-0002-6287-020X
Edmiston, Kristen K.
Petricoin, Emanuel F.
Stringer-Reasor, Erica
Falkson, Carla I.
Majure, Melanie
Mukhtar, Rita A.
Helsten, Teresa L.
Moulder, Stacy L.
Robinson, Patricia A.
Wulfkuhle, Julia D.
Brown-Swigart, Lamorna http://orcid.org/0000-0003-2076-5177
Buxton, Meredith
Clennell, Julia L.
Paoloni, Melissa
Sanil, Ashish
Berry, Scott
Asare, Smita M.
Wilson, Amy
Hirst, Gillian L. http://orcid.org/0000-0002-4502-0035
Singhrao, Ruby
Asare, Adam L.
Matthews, Jeffrey B.
Hylton, Nola M. http://orcid.org/0000-0002-6747-1662
DeMichele, Angela http://orcid.org/0000-0003-1297-4251
Melisko, Michelle
Perlmutter, Jane
Rugo, Hope S.
Fraser Symmans, W. http://orcid.org/0000-0002-1526-184X
van‘t Veer, Laura J. http://orcid.org/0000-0002-9838-8298
Berry, Donald A.
Esserman, Laura J. http://orcid.org/0000-0001-9202-4568
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 23 November 2020
Accepted: 26 August 2021
First Online: 5 October 2021
Competing interests
: Doug Yee has received unrelated research support from Boehringer Ingleheim. Claudine Isaacs has received consulting fees from Seattle Genetics, Genentech, AstraZeneca, Novartis, PUMA, Pfizer, and Esai. Christina Yau has consulted for NantOmics, LLC, part of the NantWorks network. Paul Haluska was employed at BMS after the work was conducted on this paper and currently holds stock options. A. Jo Chein reports institutional research support from Seagen, Merck, Amgen and Puma Biotechnology. Lajos Pusztai has received consulting fees and honoraria from Seattle Genetics, Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, and Daiichi, institutional research support from Seattle Genetics, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. Barbara Haley reports institutional support from Pfizer, Lilly, Daiichi Sankyo, Roche, Puma, Astra Zeneca and Sanofi. Judy C. Boughey has received support from Eli Lilly. Debu Tripathy has received support from Novartis, Pfizer, AstraZeneca, GSK and Immunomedics. Amy S. Clark has received unrelated research support from Novartis. Hyo S. Han reports institutional support from GlaxoSmithKline, Abbvie, Prescient, G1 therapeutics, Marker Therapeutics, Novartis, Horizon Pharma, Pfizer, Seattle Genetics, Arvinas and Zymeworks, and is part of Lilly’s speaker’s bureau. E.F. Petricoin reports: leadership roles with: Perthera and Ceres Nanosciences; stock or other ownership interests in Perthera, Ceres Nanosciences and Avant Diagnostics; consulting or advisory roles with Perthera, Ceres Nanosciences, AZGen, Avant Diagnostics; institutional research support from Ceres Nanosciences, GlaxoSmithKline), Abbvie, Symphogen, and Genentech; patents, royalties, other intellectual property from National Institutes of Health patents licensing fee distribution/royalty, co-inventor on filed George Mason University–assigned patents related to phosphorylated HER2 and EGFR response predictors for HER family-directed therapeutics, as such can receive royalties and licensing distribution on any licensed IP; travel, accommodations, expenses received from Perthera and Ceres Nanosciences. Erica Stringer-Reasor reports receiving research funds or consulting fees from Lilly, Immunomedics and Mylan. J.D. Wulfkuhle received honoraria from DAVA Oncology and consults for Baylor College of Medicine. Angela DeMichele has received honoraria or consulting fees from Pfizer and Context Therapeutics and reports institutional research support from Novartis, Pfizer, Genentech, Calithera and Menarini. Michelle Melisko has consulted for Biotheranostics and reports institutional research support from AstraZeneca, Novartis, KCRN Research and Puma Biotechnology. Hope Rugo reports institutional research support from Pfizer, Merck, Novartis, Lilly, Genentech, Odonate, Daiichi, Seattle Genetics, Eisai, Macrogenics, Sermonix, Boehringer Ingelheim, Polyphor, Astra Zeneca and Immunomedics, and has received honoraria from Puma Biotechnology, Mylan and Samsung. Laura J. van ‘t Veer is a part-time employee and stockholder in Agendia N.V. Laura Esserman is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative (QLHC) and received grant support from QLHC for the I-SPY2 Trial; she is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives reimbursement for her time and travel; Dr. Esserman has received unrelated research support from Merck. The remaining authors declare no competing interests.